18/07/2019: Pharegis implemented optimized procedures for state registration of pharmaceuticals in Eurasian Economic Union.
20/06/2019: Pharegis updated timelines and practical approaches for Russian and EEU GMP inspection applications and procedures.
03/04/2019: Renewed general monographs of Russian state pharmacopeia XIV ed. have been analyzed.
Global industry news
Pharma megamergers need to go under a microscope, Senators tell FTC
J&J's Erleada scores metastatic prostate cancer nod in battle with Pfizer-Astellas' Xtandi
Biogen ramps up its SMA rivalry with Novartis with new Spinraza trial
+7 495 442 37 85
+7 985 908 58 18
Registration of Medical Drugs in Russia
Registration of Pharmaceuticals in Russia
Registration of Pharmaceutical Dossier Variations in Russia
Registration of Pharmaceuticals in CIS
Clinical Studies in Russia
Clinical Studies for Registration of Pharmaceuticals in Russia
International Phase III Clinical Studies
Phase I, Phase II (IIa, IIb) Clinical Studies
Preclinical Studies in Russia
Preclinical Studies for Registration of Pharmaceuticals in Russia
Preclinical Studies for Registration of Biopharmaceuticals in Russia
In Vitro Preclinical Studies in Russia
Regulatory Consulting in Russia and EEU
Certification of Medical Drugs and Medical Devices in Russia
Registration of Medical Devices in Russia
Russian GMP inspection of pharmaceutical manufacturers
Regulatory Events Russia
Russian Regulatory News
You are here:
Pharegis LLC / ООО "Фареджис"
3-1 Begovaya str. ("NordStar Tower", 31st flr), Moscow, Russia 125284
Legal & postal address:
11A-11 Cherkizovskaya B. str., Moscow, Russia 107392
TAX ID (TIN): 7718278100
+7 495 442 37 85 9am-6pm GMT+3
+ 7 495 442 37 85
+ 7 985 908 58 18
Send an Email
Send a copy to yourself
SHARE THIS BY:
Create an account
Forgot your username?
Forgot your password?
Drugs.com - New Drug Approvals
FDA Approves Keytruda (pembrolizumab) plus Lenvima (lenvatinib) Combination Treatment for Patients with Certain Types of Endometrial Carcinoma
FDA Approves Ibsrela (tenapanor) for the Treatment of Irritable Bowel Syndrome with Constipation
FDA Approves Nucala (mepolizumab) for Six to 11-Year-Old Children with Severe Eosinophilic Asthma
FDA Approves Gvoke (glucagon), the First Ready-to-use Stable Liquid Glucagon for Severe Hypoglycemia
FDA Approves Ofev (nintedanib) for Interstitial Lung Disease Associated with Systemic Sclerosis or Scleroderma (SSc-ILD)
News and press releases
Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 10-12 September 2019, CVMP, 13/09/2019
EMA to provide guidance on avoiding nitrosamines in human medicines, , 13/09/2019
EMA to review ranitidine medicines following detection of NDMA, , 13/09/2019
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 2-5 September 2019, PRAC, 06/09/2019
Drugs.com - Clinical Trials
FDA Accepts Merck’s Biologics License Application (BLA) and Grants Priority Review for V920, the Company’s Investigational Vaccine for Ebola Zaire Virus
Innovation Pharmaceuticals Announces Successful Formulation of Oral Brilacidin Tablets; Upcoming Clinical Trial to Target Delivery to the Colon
BEVERLY, MA –...
Tiziana Life Sciences Announces FDA Approval to Initiate Phase I Clinical Trial with Orally Administered Foralumab in Healthy Volunteers
London, 16 September,...
Akari Therapeutics’ Nomacopan Granted U.S. Orphan Drug Designation for Bullous Pemphigoid
NEW YORK and LONDON, Sept....
PharmaTimes: PharmaTimes Website RSS
Cosentyx bags positive results in potential new indication
NICE recommends Takhzyro
MHRA, Bill & Melinda Gates foundation team up for medicine safety whilst pregnant
Happify, Sanofi to advance digital therapeutics for MS
Acceleron abandons muscular dystrophy drug
Terms of Service
Sample Non-Disclosure Agreement